Carcinoma da próstata metastático resistente à castração - novas abordagens terapêuticas

Rodrigues, S.; Dores, Marco; Metrogos, V.; Rodrigues, Michele Ângela; Gomes, Pms; Cabrita, Miguel A.; Rosa, Geraldine López De la; Coutinho, Aníbal; Neves, Josiele de Lima

doi:10.1016/s2341-4022(14)50008-0

Cited by 3 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The D9902B study included 512 men with asymptomatic or metastatic CPRC with mild symptoms, divided into two groups, one vaccinated (n = 341) and one control (n = 171). The results of the study showed a 22% reduction in the risk of death, and a 31.7% probability of survival with the use of sipuleucel-T compared to 23% in the control group [10][11][12]. The adverse events after the use of sipuleucel-T included chills, fever, muscle pain, asthenia, headache, vomiting [10].…”

Section: Methodsmentioning

confidence: 99%

“…Nonetheless, the use of active immunotherapy still raises some questions regarding the best time to initiate the treatment, and possible combinations of sipuleucel-T with other therapeutic drugs. It is also necessary to take it in account the very high cost and the laboratory and clinical complexity for the use of this type of therapy, which can limit its clinical use in health centers worldwide [11,12].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines Against Different Types of Cancer: Literature Review

Dias¹,

Melo²

2021

J Pharma Res Rep

View full text Add to dashboard Cite

According to the World Health Organization, in 2018, cancer was considered the second leading cause of death in the world, corresponding to 9.6 million deaths. Faced with this situation, some alternatives to combat tumors in some organs were developed, such as immunotherapy involving vaccines. Among the vaccines already developed, Sipuleucel-T (Provenge®) can be mentioned, that has been approved by the Food and Drug Administration in 2010 for cases of metastatic prostate cancer; prophylactic bivalent and quadrivalent vaccines to human papillomavirus; the nanoparticulate liposomal RNA vaccine, the melanoma FixVac (BNT111); peptide-based vaccines, such as carcinoembryonic antigen, and those that involve antigen-loaded dendritic cells for the treatment of colorectal cancer, as well as colorectal cancer stem cell-based vaccines and, for cases of ovarian cancer, dendritic cell vaccines. In relation to breast cancer, research is aimed at both immunotherapy with dendritic cells pulsed with tumor antigens and vaccines that have a combined therapy of dendritic cells and Natural Killer cells. In general, vaccines promote the induction of helper and cytotoxic cells to thereby eliminate tumor cells. This characteristic of using dendritic cells with tumor antigens already processed and presented on the cell surface allows the questioning about the use of the term “vaccine”, since it does not correspond to conventional vaccines. Thus, the studies carried out in this area of immunotherapy, although complex and expensive, show promise in the treatment of several types of cancer, with great possibilities of positively impacting the lives of all those who suffer from the disease.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Vaccines Against Different Types of Cancer: Literature Review

Dias¹,

Melo²

2021

J Pharma Res Rep

View full text Add to dashboard Cite

show abstract

“…Câncer de próstata resistente a castração metastático (CPRCM) é definido como a neoplasia que apresenta progressão apesar dos níveis de testosterona circulante baixos (Tan & Haaland, 2014). Até o início da última década, o CPRCM era considerado refratário à hormonioterapia, e com proliferação celular independente do bloqueio do receptor androgênico (Rodrigues et al, 2014). Com o avanço no desenvolvimento de novas tecnologias foi possível o desenvolvimento de dois novos compostos para o tratamento de CPRCM, ainda com atuação na sinalização do receptor androgênico, a enzalutamida e o acetato de abiraterona (Mottet et al, 2014).…”

Section: Introductionunclassified

Custo por evento evitado da enzalutamida versus abiraterona associada à prednisona em homens com câncer de próstata resistente à castração metastático, sob a perspectiva do Sistema de Saúde Suplementar no Brasil

Stefani¹,

Teich²,

Fay³

et al. 2015

JBES

View full text Add to dashboard Cite

Introdução: O câncer de próstata resistente a castração metastático (CPRCM) é definido como uma neoplasia proliferativa contínua. Com o avanço de novas tecnologias, novos tratamentos foram desenvolvidos: enzalutamida (ENZ) e acetato de abiraterona + prednisona (AA+P). Este estudo analisou o custo por evento evitado (COPE) da ENZ e AA+P no tratamento do CPRCM após quimioterapia, sob a perspectiva do Sistema de Saúde Suplementar, utilizando os desfechos de eficácia sobrevida global (SG) e sobrevida livre de progressão radiográfica (SLPr). Métodos: Uma análise de custo foi realizada baseada nos estudos pivotais de ENZ e AA+P após uso de docetaxel a fim de calcular o COPE. Dois parâmetros foram necessários: custo anual de tratamento (CAT) e número necessário a tratar (NNT). O NNT é o inverso da redução de risco absoluto (RRA). O COPE é o CAT multiplicado pelo NNT. Resultados: Os resultados de CAT destacam uma economia de R$ 1.006,00

show abstract

“…(Lee, 2018) Até a alguns anos, a terapia de privação de andrógeno era a técnica mais adequada para tratamento do câncer de próstata metastático, porém a mesma se mostrava ineficiente após um curto espaço de tempo, em média de 12 a 18 meses, devido à resistência desenvolvida pelas células tumorais à castração. (Rodrigues, 2014) O câncer de próstata se desenvolve geralmente na zona periférica da próstata e em sua fase inicial costuma ser assintomático, podendo levar a um diagnóstico tardio, o que aumenta os índices de mortalidade da doença. (Lima et al, 2017) Quando sintomático, os pacientes apresentam aumento urinário, dificuldade ou dor para iniciar a micção e dificuldade de esvaziamento da bexiga, semelhantes a um quadro de hiperplasia prostática benigna (HPB).…”

Section: Objetivos Específicosunclassified

Avaliação da especificidade biológica do radiofármaco PSMA-HBED-CC-68Ga em modelos tumorais in vitro e in vivo

Vivaldini¹

View full text Add to dashboard Cite

Diagnostic images in nuclear medicine, obtained with the administration of radiopharmaceuticals, present great advances due to their high specificity and sensitivity, increasing the reliability of the results. This work focused on previous studies based on the 68 Ga radiolabeled bifunctional chelator associated to PSMA receptor inhibitor peptide, compound that has been shown to be capable of diagnosing prostate cancer recurrences and metastases when used in diagnostic imaging, also assisting in the early diagnosis of the disease. PSMA-HBED-CC-68 Ga radiolabelling studies (non-automated method) were performed to increase the labeling yield, using thin layer chromatography and high performance liquid chromatography for radiochemical purity analyzes, evaluating 68 GaCl3 eluates from 68 Ge/ 68 Ga generators from different manufacturers. From buffer suitability studies and radiolabelling conditions, a prior formulation was obtained for the development of a 68 Ga ready-label kit, including the study of the influence of generator eluate quality on labeling yield. For the evaluation of the in vivo biological specificity of the PSMA-HBED-CC-68 Ga, biodistribution studies were performed on healthy and tumor-growing animals. Radiopharmaceutical specificity was also evaluated in vitro, with tumor cell binding speed, saturation and competition studies. In vivo and in vitro studies have shown radiopharmaceutical specificity for prostate cancer cells and tumors, contributing to consolidate the preclinical studies required for radiopharmaceutical registration.

show abstract

Carcinoma da próstata metastático resistente à castração - novas abordagens terapêuticas

Cited by 3 publications

References 28 publications

Vaccines Against Different Types of Cancer: Literature Review

Vaccines Against Different Types of Cancer: Literature Review

Custo por evento evitado da enzalutamida versus abiraterona associada à prednisona em homens com câncer de próstata resistente à castração metastático, sob a perspectiva do Sistema de Saúde Suplementar no Brasil

Avaliação da especificidade biológica do radiofármaco PSMA-HBED-CC-68Ga em modelos tumorais in vitro e in vivo

Contact Info

Product

Resources

About